Chemomab Therapeutics (CMMB) Other Accumulated Expenses (2017 - 2019)

Chemomab Therapeutics (CMMB) has 3 years of Other Accumulated Expenses data on file, last reported at $2.3 million in Q4 2019.

• Quarterly Other Accumulated Expenses rose 34.58% year-over-year to $2.3 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $2.3 million (up 34.58% YoY) and the FY2019 annual result came in at $2.3 million, up 34.58% from the prior year.
• Other Accumulated Expenses slipped to $2.3 million in Q4 2019, from $3.8 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $3.8 million in Q3 2019 to a low of $1.6 million in Q2 2019.
• A 3-year average of $2.4 million and a median of $2.3 million in 2019 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2018 — Other Accumulated Expenses retreated 28.35% — and 2019, when it jumped 34.58%.
• Tracing CMMB's Other Accumulated Expenses over 3 years: stood at $2.4 million in 2017, then dropped by 28.35% to $1.7 million in 2018, then surged by 34.58% to $2.3 million in 2019.
• The last three Other Accumulated Expenses figures came in at $2.3 million (Q4 2019), $3.8 million (Q3 2019), and $1.6 million (Q2 2019), per Business Quant data.